UBS released a research report stating that after maintaining the “buy” rating of Hewang Pharmaceuticals (00013.HK) and including surufatinib to treat first-line PDAC in the product pipeline forecast, the target price was raised from HK$35.7 to HK$39.
瑞银：维持和黄医药(00013.HK)“买入”评级 目标价升至39港元
UBS: Maintaining Hewang Pharmaceuticals (00013.HK)'s “Buy” Rating and Raising the Target Price to HK$39
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.